Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive heterogeneous blood cancer derived from hematopoietic stem cells. Tumor-stromal interactions in AML are of importance for disease development and therapy resistance, and bone marrow stroma seem like an attractive therapeutic target. Of particular interes...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.654817/full |
| _version_ | 1828966077684514816 |
|---|---|
| author | Kristine Yttersian Sletta Oriol Castells Bjørn Tore Gjertsen Bjørn Tore Gjertsen |
| author_facet | Kristine Yttersian Sletta Oriol Castells Bjørn Tore Gjertsen Bjørn Tore Gjertsen |
| author_sort | Kristine Yttersian Sletta |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is an aggressive heterogeneous blood cancer derived from hematopoietic stem cells. Tumor-stromal interactions in AML are of importance for disease development and therapy resistance, and bone marrow stroma seem like an attractive therapeutic target. Of particular interest is colony stimulating factor 1 receptor (CSF1R, M-CSFR, c-FMS, CD115) and its role in regulating plasticity of tumor-associated macrophages. We discuss first the potential of CSF1R-targeted therapy as an attractive concept with regards to the tumor microenvironment in the bone marrow niche. A second therapy approach, supported by preclinical research, also suggests that CSF1R-targeted therapy may increase the beneficial effect of conventional and novel therapeutics. Experimental evidence positioning inhibitors of CSF1R as treatment should, together with data from preclinical and early phase clinical trials, facilitate translation and clinical development of CSF1R-targeted therapy for AML. |
| first_indexed | 2024-12-14T11:25:35Z |
| format | Article |
| id | doaj.art-15c786252b5345b7a9592256c24657a5 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T11:25:35Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-15c786252b5345b7a9592256c24657a52022-12-21T23:03:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.654817654817Colony Stimulating Factor 1 Receptor in Acute Myeloid LeukemiaKristine Yttersian Sletta0Oriol Castells1Bjørn Tore Gjertsen2Bjørn Tore Gjertsen3CCBIO, Centre for Cancer Biomarkers, Department of Clinical Science, Precision Oncology Research Group, University of Bergen, Bergen, NorwayDepartment of Medicine, Hematology Section, Haukeland University Hospital, Bergen, NorwayCCBIO, Centre for Cancer Biomarkers, Department of Clinical Science, Precision Oncology Research Group, University of Bergen, Bergen, NorwayDepartment of Medicine, Hematology Section, Haukeland University Hospital, Bergen, NorwayAcute myeloid leukemia (AML) is an aggressive heterogeneous blood cancer derived from hematopoietic stem cells. Tumor-stromal interactions in AML are of importance for disease development and therapy resistance, and bone marrow stroma seem like an attractive therapeutic target. Of particular interest is colony stimulating factor 1 receptor (CSF1R, M-CSFR, c-FMS, CD115) and its role in regulating plasticity of tumor-associated macrophages. We discuss first the potential of CSF1R-targeted therapy as an attractive concept with regards to the tumor microenvironment in the bone marrow niche. A second therapy approach, supported by preclinical research, also suggests that CSF1R-targeted therapy may increase the beneficial effect of conventional and novel therapeutics. Experimental evidence positioning inhibitors of CSF1R as treatment should, together with data from preclinical and early phase clinical trials, facilitate translation and clinical development of CSF1R-targeted therapy for AML.https://www.frontiersin.org/articles/10.3389/fonc.2021.654817/fullcolony stimulating factor 1 receptortumor-stromasignal transductionbiomarkersacute myeloid leukemiatargeted therapy |
| spellingShingle | Kristine Yttersian Sletta Oriol Castells Bjørn Tore Gjertsen Bjørn Tore Gjertsen Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia Frontiers in Oncology colony stimulating factor 1 receptor tumor-stroma signal transduction biomarkers acute myeloid leukemia targeted therapy |
| title | Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia |
| title_full | Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia |
| title_fullStr | Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia |
| title_full_unstemmed | Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia |
| title_short | Colony Stimulating Factor 1 Receptor in Acute Myeloid Leukemia |
| title_sort | colony stimulating factor 1 receptor in acute myeloid leukemia |
| topic | colony stimulating factor 1 receptor tumor-stroma signal transduction biomarkers acute myeloid leukemia targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.654817/full |
| work_keys_str_mv | AT kristineyttersiansletta colonystimulatingfactor1receptorinacutemyeloidleukemia AT oriolcastells colonystimulatingfactor1receptorinacutemyeloidleukemia AT bjørntoregjertsen colonystimulatingfactor1receptorinacutemyeloidleukemia AT bjørntoregjertsen colonystimulatingfactor1receptorinacutemyeloidleukemia |